MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

multiple sclerosis

  • Home
  • multiple sclerosis
  • Page 2
Pregnancy and Disease Outcomes in Women with Moderate to Severe Multiple Sclerosis Disability
Posted inAllergy & Immunology Clinical Updates OB/GYN & Women's Health

Pregnancy and Disease Outcomes in Women with Moderate to Severe Multiple Sclerosis Disability

Posted by By MedXY 09/24/2025
This study evaluates how pregnancy affects relapse rates and long-term disability in women with moderate to severe multiple sclerosis (MS), showing pregnancy reduces relapse during gestation without worsening long-term disability progression.
Read More
Serum Alpha-Linolenic Acid and Long-Term Multiple Sclerosis Activity and Progression: Insights from the BENEFIT Study
Posted inAllergy & Immunology news Rheumatology Specialties

Serum Alpha-Linolenic Acid and Long-Term Multiple Sclerosis Activity and Progression: Insights from the BENEFIT Study

Posted by By MedXY 08/20/2025
Higher baseline serum alpha-linolenic acid levels predict reduced multiple sclerosis activity, relapses, and disability progression up to 11 years post clinical onset in a large prospective study.
Read More
Therapeutic Strategies for Disease-Modifying Therapy Management in Pregnant Women With Multiple Sclerosis: Relapse Risk and Clinical Implications
Posted inAllergy & Immunology Clinical Updates news Rheumatology Specialties

Therapeutic Strategies for Disease-Modifying Therapy Management in Pregnant Women With Multiple Sclerosis: Relapse Risk and Clinical Implications

Posted by By MedXY 08/04/2025
Managing disease-modifying therapies (DMTs) during pregnancy in women with multiple sclerosis significantly affects relapse risk, with anti-CD20 strategies demonstrating superior protection compared to other approaches.
Read More
Fenebrutinib in Relapsing Multiple Sclerosis: New Evidence from the FENopta Phase 2 Trial
Posted inClinical Updates Medical News Rheumatology Specialties

Fenebrutinib in Relapsing Multiple Sclerosis: New Evidence from the FENopta Phase 2 Trial

Posted by By MedXY 08/02/2025
Fenebrutinib, a selective BTK inhibitor, demonstrated significant reduction in new brain lesions and low relapse rates in relapsing multiple sclerosis, with a favorable safety profile in the FENopta phase 2 trial.
Read More
Comparative Efficacy and Safety of Tolebrutinib in Multiple Sclerosis: Insights from Recent Phase 3 Trials
Posted inAllergy & Immunology Clinical Updates news Rheumatology Specialties

Comparative Efficacy and Safety of Tolebrutinib in Multiple Sclerosis: Insights from Recent Phase 3 Trials

Posted by By MedXY 08/02/2025
Tolebrutinib reduced disability progression in nonrelapsing secondary progressive MS but did not surpass teriflunomide in reducing relapse rates in relapsing MS. Safety signals include elevated liver enzymes and minor bleeding risks.
Read More

Posts pagination

Previous page 1 2
  • Stratifying Risk for Further Retinal Intervention After Laser Retinopexy: The Impact of Cumulative Clinical Factors
  • Visual Performance of a Refractive Extended Depth of Field Intraocular Lens in Monovision and Emmetropic Settings: A Comprehensive Review
  • Intraoperative Botulinum Toxin Injection to Reduce Postoperative Sialocele After Parotidectomy: A Retrospective Cohort Analysis
  • Outcomes of Laryngeal Carcinoma Treatment in Female Patients: A Multicenter Retrospective Analysis
  • Imaging-Guided Classification and Diagnostic Pathways for Appendiceal Abscesses: Practical Takeaways from the 2025 Italian Consensus
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification semaglutide SGLT2 inhibitors stroke type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top